Cannara Biotech Inc.
TSX:LOVE.TO · Toronto Stock Exchange
+$0.02 today
Vol 0.04M · Avg 0.04M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
TSX:LOVE.TO · Revenue to Net Income
Key Ratios
Analysis
$112.7M of revenue converted into $11.8M of net income for the selected period. Gross margin is 39.0% and net margin is 10.7%, showing how much revenue survives after costs and taxes. EPS is $0.13, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $107.3M +31.3% | $81.7M +42.8% | $57.3M +59.8% | $35.8M +110.6% | $17.0M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $60.1M +15.7% | $52.0M +73.0% | $30.0M +62.2% | $18.5M +175.3% | $6.7M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $47.2M +58.5% | $29.8M +9.4% | $27.2M +57.1% | $17.3M +68.3% | $10.3M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 44.0% +7.6pp | 36.4% -11.1pp | 47.6% -0.8pp | 48.4% -12.1pp | 60.5% | 9.8% | 28.9% | 38.3% |
| Research & Development | $711.2K -36.6% | $1.1M +8.7% | $1.0M -18.0% | $1.3M -34.1% | $1.9M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $23.2M +17.9% | $19.6M +45.3% | $13.5M +34.8% | $10.0M +37.3% | $7.3M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $25.0M +27.0% | $19.7M +28.5% | $15.3M +24.2% | $12.4M +23.6% | $10.0M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $6.4M +0.8% | $6.4M +28.5% | $4.9M +26.1% | $3.9M +29.6% | $3.0M | $374.2M | $1.2B | $631.8M |
| EBITDA | $28.2M +85.8% | $15.2M -3.8% | $15.8M +65.3% | $9.5M +195.9% | $3.2M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 26.3% +7.7pp | 18.6% -9.0pp | 27.5% +0.9pp | 26.6% +7.7pp | 18.9% | 5.6% | 46.3% | 42.0% |
| Operating Income | $22.2M +120.2% | $10.1M -15.2% | $11.9M +223.7% | $3.7M +1806.6% | $192.6K | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 20.7% +8.4pp | 12.3% -8.4pp | 20.8% +10.5pp | 10.2% +9.1pp | 1.1% | 16.6% | 24.1% | 22.0% |
| Interest Income | $280.9K +57.0% | $179.0K -25.3% | $239.5K +158.4% | $92.7K +75.6% | $52.8K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $4.4M -23.1% | $5.7M +6.9% | $5.3M +59.9% | $3.3M +92.1% | $1.7M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$4.1M +26.7% | -$5.6M -13.2% | -$4.9M -87.5% | -$2.6M -47.6% | -$1.8M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $18.1M +303.6% | $4.5M -35.4% | $6.9M +201.3% | $2.3M +250.9% | -$1.5M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 16.9% +11.4pp | 5.5% -6.6pp | 12.1% +5.7pp | 6.4% +15.4pp | -9.0% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $5.0M +356.9% | -$2.0M | $0 +100.0% | -$551.4K -135.2% | $1.6M | $1.3B | -$1.6B | $745.2M |
| Net Income | $13.1M +103.1% | $6.4M -7.3% | $6.9M +201.3% | $2.3M +174.5% | -$3.1M | $4.9B | $4.8B | $4.7B |
| Net Margin | 12.2% +4.3pp | 7.9% -4.3pp | 12.1% +5.7pp | 6.4% +24.6pp | -18.2% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $0 +95.8% | $0 -8.1% | $0 +195.8% | $0 +165.1% | -$0 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $0 +98.6% | $0 -9.4% | $0 +196.9% | $0 +164.9% | -$0 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $93.4M +3.7% | $90.1M +0.9% | $89.3M +1.9% | $87.7M +14.6% | $76.5M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $92.4M +1.1% | $91.4M +2.3% | $89.3M +1.7% | $87.8M +14.8% | $76.5M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Auxly Cannabis Group Inc.
TSX:XLY.TO
$257.70M
Quipt Home Medical Corp.
QIPT.TO
$221.44M
Cardiol Therapeutics Inc.
TSX:CRDL.TO
$171.76M
BioSyent Inc.
RX.V
$160.02M
Grown Rogue International Inc.
GRIN.CN
$149.96M
HLS Therapeutics Inc.
TSX:HLS.TO
$133.86M
Jushi Holdings Inc.
JUSH.CN
$133.80M
Satellos Bioscience Inc.
TSX:MSCL.TO
$125.22M
Helix BioPharma Corp.
TSX:HBP.TO
$108.46M
Decibel Cannabis Company Inc.
DB.V
$69.23M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does LOVE.TO generate?
Cannara Biotech Inc. (LOVE.TO) reported $107.32M of revenue in fiscal 2025.
Is LOVE.TO profitable?
Cannara Biotech Inc. (LOVE.TO) reported $13.08M of net income, with a net margin of 12.2%.
Explore More
Continue the stock analysis
Jump to another research area for this company.